Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Withdrawn Phase 2 Trials for Flotetuzumab (DB15223)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0115568 (Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm) | Withdrawn | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Treatment |